When Ozempic stops producing results, it is frustrating and, for many people, alarming. But “not working” often means something specific and addressable, not that the medication has failed. Understanding the actual mechanisms behind GLP-1 plateaus and poor response changes what the right next step looks like.
How to Know If Ozempic Is Actually Not Working
First, a useful distinction. There is a difference between:
- Ozempic not reducing appetite at all (rare, and usually a sign of a specific problem)
- Ozempic working, but weight loss has slowed or stopped (common, normal, and expected)
If you feel no appetite reduction whatsoever even at doses above 0.5 mg, that suggests a potential absorption issue, dose timing problem, or occasionally a poor response to the drug. If you do feel some appetite reduction but the scale has stopped moving, that is almost always a plateau driven by metabolic adaptation.
The Most Common Reason: Dose Is Not Therapeutic Yet
The 0.25 mg starting dose of Ozempic is not a therapeutic dose for weight loss. It is a tolerability ramp-up dose designed to minimize side effects during initial exposure.
In clinical trials, the dose ranges that produced significant weight loss were 0.5 mg, 1.0 mg, and 2.0 mg (or 2.4 mg for Wegovy). The standard titration schedule reaches the lowest therapeutic dose at week four and the maximum approved dose for Ozempic at week twelve or later for the 2 mg dose.
Many people on Ozempic who report it “not working” are still on 0.25 mg or 0.5 mg and have not yet reached a dose that produces robust weight loss. This is the most straightforward and common cause, and the solution is continued titration per the approved schedule.
Weight Loss Plateaus on GLP-1 Medications
Weight loss plateaus are a normal feature of GLP-1 therapy, not a sign of drug failure.
Clinical trial data from the STEP program shows that most weight loss occurs in the first 20 to 36 weeks after reaching the therapeutic dose. After this period, the rate of loss slows substantially, and many patients reach a new, lower set point where the medication maintains weight without producing further loss.
The reason is adaptive thermogenesis, a well-documented biological response to caloric restriction and weight loss. When the body loses weight, it responds by:
- Reducing resting metabolic rate (burning fewer calories at rest)
- Increasing the hormonal drive for hunger (leptin decreases, ghrelin increases)
- Improving caloric efficiency (extracting more energy from the same food)
These adaptations are the body’s defense of its prior weight. GLP-1 medications reduce appetite but do not fully overcome these metabolic compensations, which is why weight loss slows and eventually plateaus at most doses.
A plateau after significant weight loss is the drug working as designed, not failing.
Other Reasons Ozempic May Not Be Working
Beyond dose and plateau, several other factors can reduce Ozempic’s effectiveness:
Injection Site Problems
Repeated injection in the same area creates lipohypertrophy, a buildup of scar tissue in the subcutaneous fat. Lipohypertrophic tissue significantly reduces drug absorption. The medication is delivered but not absorbed into circulation at the expected rate, effectively giving a lower dose than intended.
The fix is systematic injection site rotation: alternating between the abdomen, thigh, and upper arm, and within each area, rotating to a new spot at least 1 inch from any recent injection.
Dietary Patterns That Counteract the Medication
Ozempic reduces hunger, but it does not eliminate the ability to overeat. Highly palatable, calorie-dense foods (processed foods, refined carbohydrates, high-fat snacks) can override the appetite reduction signal. If weight loss has stalled, a dietary audit looking at actual caloric intake, not just perceived intake, is worthwhile.
Tracking food for two weeks provides objective data that often reveals more eating than patients estimate, particularly from beverages, condiments, and untracked snacks.
Hormonal or Medical Conditions
Uncontrolled hypothyroidism, insulin resistance, polycystic ovary syndrome (PCOS), and Cushing’s syndrome can all create resistance to weight loss that GLP-1 medications cannot fully overcome. If you have risk factors for these conditions and have not been screened recently, that is worth discussing with your physician.
Drug Interactions
Certain medications can directly or indirectly counteract GLP-1 effects on weight. Corticosteroids, antipsychotics, some antidepressants (particularly mirtazapine and olanzapine), and insulin-sensitizing drugs can affect weight outcomes. Review your full medication list with your prescribing physician if you are concerned about interactions.
Summary: Causes and What to Do
| Situation | Likely Cause | Action |
|---|---|---|
| No appetite reduction at any dose | Absorption issue or non-response | Check injection technique; discuss with physician |
| Plateau after 3-6 months at max dose | Metabolic adaptation | Accept plateau; consider switch to tirzepatide |
| Plateau while still titrating up | Not at therapeutic dose yet | Continue titration per schedule |
| Loss slowing but not stopped | Normal dose-response curve | Maintain current dose; reassess at 6 months |
| Never lost weight from the start | Injection site problem, dose issue, or non-response | Rotate injection sites; verify dose; consult physician |
When to Consider Switching to Mounjaro
For patients who have reached and tolerated the maximum semaglutide dose and have hit a genuine plateau, switching to tirzepatide (Mounjaro/Zepbound) is a supported clinical option.
The SURMOUNT-5 trial demonstrated tirzepatide produces approximately 20 percent weight loss versus 14 percent for semaglutide over 72 weeks. For a patient who has plateaued at 12 to 14 percent weight loss on maximum semaglutide and has more to lose, the additional 6 percent average advantage of tirzepatide can be meaningful.
The switch involves stopping semaglutide and starting tirzepatide at its 2.5 mg introductory dose the following week, then titrating up following tirzepatide’s schedule. Dose equivalency between the two drugs is not a one-to-one conversion.
What Happens If You Stop Ozempic
The STEP 4 trial provides a clear picture of what happens when Ozempic is discontinued. Participants who stopped semaglutide after achieving weight loss regained approximately two-thirds of their lost weight within 68 weeks, while those who continued the medication maintained their results.
This finding establishes that Ozempic is a chronic medication for most people, not a short course. The weight loss benefit depends on continued use. Stopping when a plateau hits often causes more regain than the plateau cost in progress.